Agios Pharmaceuticals (AGIO) News Today $30.84 +0.44 (+1.45%) Closing price 03/27/2025 04:00 PM EasternExtended Trading$31.06 +0.22 (+0.70%) As of 03/27/2025 06:09 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Headlines Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSustainabilityTrendsBuy This Stock All Sources Trusted Sources MarketBeat Benzinga Bloomberg GuruFocus MarketWatch Motley Fool NASDAQ PR Newswire Reuters Seeking Alpha TalkMarkets The Street TipRanks The Wall Street Journal Wall Street Zen Yahoo Finance Source Sentiment refers to the positivity or negativity of each headline according to our language processing algorithm. Sentiment All Sentiments Very Positive Positive Neutral Negative Very Negative Most Recent March 2025 February 2025 January 2025 December 2024 November 2024 October 2024 September 2024 August 2024 July 2024 June 2024 May 2024 April 2024 March 2024 February 2024 January 2024 December 2023 November 2023 October 2023 September 2023 August 2023 July 2023 June 2023 May 2023 April 2023 March 2023 February 2023 January 2023 December 2022 November 2022 October 2022 September 2022 August 2022 July 2022 June 2022 May 2022 April 2022 Time Period Is Agios Pharmaceuticals, Inc. (NASDAQ:AGIO) the Best Small Cap Stock to Buy Before They Explode?March 27 at 6:54 PM | msn.comAgios Pharmaceuticals (NASDAQ:AGIO) Shares Down 4.9% - Here's What HappenedAgios Pharmaceuticals (NASDAQ:AGIO) Trading Down 4.9% - Here's What HappenedMarch 26 at 4:48 PM | marketbeat.comAgios Pharmaceuticals, Inc. (NASDAQ:AGIO) Receives Consensus Recommendation of "Moderate Buy" from BrokeragesMarch 26 at 2:57 AM | americanbankingnews.comFox Run Management L.L.C. Invests $783,000 in Agios Pharmaceuticals, Inc. (NASDAQ:AGIO)Fox Run Management L.L.C. acquired a new position in shares of Agios Pharmaceuticals, Inc. (NASDAQ:AGIO - Free Report) during the fourth quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The institutional investor acquired 23,839 shares of theMarch 25 at 5:19 AM | marketbeat.comIntech Investment Management LLC Raises Stake in Agios Pharmaceuticals, Inc. (NASDAQ:AGIO)Intech Investment Management LLC boosted its holdings in Agios Pharmaceuticals, Inc. (NASDAQ:AGIO - Free Report) by 40.7% during the fourth quarter, according to the company in its most recent disclosure with the SEC. The firm owned 28,248 shares of the biopharmaceutical company's stock after purchMarch 24, 2025 | marketbeat.comAgios Pharmaceuticals, Inc. (NASDAQ:AGIO) Given Consensus Rating of "Moderate Buy" by AnalystsShares of Agios Pharmaceuticals, Inc. (NASDAQ:AGIO - Get Free Report) have received a consensus recommendation of "Moderate Buy" from the nine ratings firms that are currently covering the company, Marketbeat Ratings reports. Four equities research analysts have rated the stock with a hold recommenMarch 22, 2025 | marketbeat.comShort Interest in Agios Pharmaceuticals, Inc. (NASDAQ:AGIO) Declines By 14.9%March 21, 2025 | americanbankingnews.comAuron Therapeutics Expands Leadership with Appointment of Glenn Goddard as Chief Financial OfficerMarch 20, 2025 | markets.businessinsider.comAgios Pharmaceuticals, Inc. (NASDAQ:AGIO) Short Interest Down 14.9% in FebruaryAgios Pharmaceuticals, Inc. (NASDAQ:AGIO - Get Free Report) was the target of a large decrease in short interest during the month of February. As of February 28th, there was short interest totalling 3,940,000 shares, a decrease of 14.9% from the February 13th total of 4,630,000 shares. Based on an average daily trading volume, of 895,400 shares, the short-interest ratio is currently 4.4 days. Approximately 7.1% of the company's shares are sold short.March 20, 2025 | marketbeat.comConnor Clark & Lunn Investment Management Ltd. Boosts Stock Position in Agios Pharmaceuticals, Inc. (NASDAQ:AGIO)Connor Clark & Lunn Investment Management Ltd. boosted its holdings in Agios Pharmaceuticals, Inc. (NASDAQ:AGIO - Free Report) by 464.3% during the 4th quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The fund owned 125,678 shares of the bMarch 17, 2025 | marketbeat.comBank of New York Mellon Corp Purchases 87,089 Shares of Agios Pharmaceuticals, Inc. (NASDAQ:AGIO)Bank of New York Mellon Corp raised its position in shares of Agios Pharmaceuticals, Inc. (NASDAQ:AGIO - Free Report) by 48.8% during the fourth quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The fund owned 265,514 shares of the biopharmaceuticaMarch 15, 2025 | marketbeat.comErste Asset Management GmbH Has $66.43 Million Position in Agios Pharmaceuticals, Inc. (NASDAQ:AGIO)Erste Asset Management GmbH lowered its stake in shares of Agios Pharmaceuticals, Inc. (NASDAQ:AGIO - Free Report) by 8.0% during the fourth quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 2,009,900 shares ofMarch 13, 2025 | marketbeat.comQ1 EPS Estimate for Agios Pharmaceuticals Lowered by AnalystAgios Pharmaceuticals, Inc. (NASDAQ:AGIO - Free Report) - Equities researchers at Zacks Research cut their Q1 2025 earnings per share (EPS) estimates for shares of Agios Pharmaceuticals in a report issued on Thursday, March 6th. Zacks Research analyst A. Chakraborty now expects that the biopharmaMarch 10, 2025 | marketbeat.comCandriam S.C.A. Sells 91,955 Shares of Agios Pharmaceuticals, Inc. (NASDAQ:AGIO)Candriam S.C.A. cut its position in Agios Pharmaceuticals, Inc. (NASDAQ:AGIO - Free Report) by 35.2% during the 4th quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The firm owned 169,550 shares of the biopharmaceutical company'March 9, 2025 | marketbeat.comBrokers Set Expectations for AGIO FY2027 EarningsAgios Pharmaceuticals, Inc. (NASDAQ:AGIO - Free Report) - Zacks Research issued their FY2027 earnings per share (EPS) estimates for shares of Agios Pharmaceuticals in a research report issued to clients and investors on Thursday, March 6th. Zacks Research analyst A. Chakraborty anticipates that tMarch 8, 2025 | marketbeat.comCelldex Therapeutics and Agios Pharmaceuticals to Present at March 2025 Investor ConferencesMarch 7, 2025 | theglobeandmail.comAgios Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) to Newly Appointed Chief Corporate Development & Strategy OfficerMarch 5, 2025 | globenewswire.comAgios to Present at Upcoming Investor ConferencesMarch 4, 2025 | globenewswire.comAgios Pharmaceuticals (NASDAQ:AGIO) Shares Down 5.9% - Should You Sell?Agios Pharmaceuticals (NASDAQ:AGIO) Trading Down 5.9% - Here's WhyMarch 3, 2025 | marketbeat.comFisher Asset Management LLC Raises Stock Position in Agios Pharmaceuticals, Inc. (NASDAQ:AGIO)Fisher Asset Management LLC boosted its position in shares of Agios Pharmaceuticals, Inc. (NASDAQ:AGIO - Free Report) by 12.3% in the 4th quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The institutional investor owned 960,661 shareMarch 3, 2025 | marketbeat.com10 Best Small-Cap Stocks to Buy NowMarch 2, 2025 | insidermonkey.comIs Agios Pharmaceuticals, Inc. (AGIO) the Best Small-Cap Stock to Buy Now?March 1, 2025 | insidermonkey.comResearch Analysts Issue Forecasts for AGIO Q1 EarningsAgios Pharmaceuticals, Inc. (NASDAQ:AGIO - Free Report) - Stock analysts at HC Wainwright issued their Q1 2025 EPS estimates for Agios Pharmaceuticals in a research report issued to clients and investors on Monday, February 24th. HC Wainwright analyst E. Bodnar expects that the biopharmaceuticalFebruary 26, 2025 | marketbeat.com45,817 Shares in Agios Pharmaceuticals, Inc. (NASDAQ:AGIO) Bought by Y Intercept Hong Kong LtdY Intercept Hong Kong Ltd bought a new position in shares of Agios Pharmaceuticals, Inc. (NASDAQ:AGIO - Free Report) during the 4th quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The institutional investor bought 45,817 shares of the biopharmacFebruary 26, 2025 | marketbeat.comWhat is HC Wainwright's Forecast for AGIO Q4 Earnings?Agios Pharmaceuticals, Inc. (NASDAQ:AGIO - Free Report) - Stock analysts at HC Wainwright issued their Q4 2025 earnings per share (EPS) estimates for Agios Pharmaceuticals in a report issued on Monday, February 24th. HC Wainwright analyst E. Bodnar forecasts that the biopharmaceutical company wilFebruary 25, 2025 | marketbeat.comAgios Pharmaceuticals initiated with a Buy at H.C. WainwrightFebruary 24, 2025 | markets.businessinsider.comAgios Pharmaceuticals (NASDAQ:AGIO) Coverage Initiated at HC WainwrightHC Wainwright began coverage on shares of Agios Pharmaceuticals in a report on Monday. They issued a "buy" rating and a $58.00 price objective for the company.February 24, 2025 | marketbeat.comAgios Pharmaceuticals, Inc. (NASDAQ:AGIO) Receives Consensus Rating of "Moderate Buy" from AnalystsShares of Agios Pharmaceuticals, Inc. (NASDAQ:AGIO - Get Free Report) have been given a consensus rating of "Moderate Buy" by the eight research firms that are presently covering the company, MarketBeat.com reports. Four investment analysts have rated the stock with a hold rating and four have giveFebruary 24, 2025 | marketbeat.comAgios Pharmaceuticals (NASDAQ:AGIO) Releases Quarterly Earnings Results, Misses Estimates By $0.05 EPSAgios Pharmaceuticals (NASDAQ:AGIO - Get Free Report) issued its quarterly earnings results on Thursday. The biopharmaceutical company reported ($1.74) earnings per share (EPS) for the quarter, missing the consensus estimate of ($1.69) by ($0.05). Agios Pharmaceuticals had a net margin of 1,845.92% and a negative return on equity of 2.51%.February 21, 2025 | marketbeat.comAgios to Present at the TD Cowen 45th Annual Healthcare Conference on March 3, 2025February 20, 2025 | globenewswire.comAgios Pharmaceuticals, Inc. (NASDAQ:AGIO) Q4 2024 Earnings Call TranscriptFebruary 19, 2025 | insidermonkey.comAgios Pharmaceuticals, Inc. (NASDAQ:AGIO) Short Interest Down 6.0% in JanuaryAgios Pharmaceuticals, Inc. (NASDAQ:AGIO - Get Free Report) was the target of a large decline in short interest in the month of January. As of January 31st, there was short interest totalling 5,030,000 shares, a decline of 6.0% from the January 15th total of 5,350,000 shares. Based on an average daily trading volume, of 882,500 shares, the days-to-cover ratio is currently 5.7 days. Approximately 9.1% of the shares of the company are short sold.February 18, 2025 | marketbeat.comAgios Pharmaceuticals (NASDAQ:AGIO) Stock Rating Lowered by StockNews.comStockNews.com lowered shares of Agios Pharmaceuticals from a "hold" rating to a "sell" rating in a research report on Friday.February 15, 2025 | marketbeat.comScotiabank Sticks to Its Buy Rating for Agios Pharma (AGIO)February 14, 2025 | markets.businessinsider.comAgios Pharmaceuticals price target lowered to $74 from $75 at ScotiabankFebruary 14, 2025 | markets.businessinsider.comAgios Pharmaceuticals: Liver Toxicity Issues May Threaten Thalassemia Approval (Rating Downgrade)February 14, 2025 | seekingalpha.comAgios Pharmaceuticals Inc (AGIO) Q4 2024 Earnings Call Highlights: Robust Revenue Growth and ...February 14, 2025 | finance.yahoo.comAgios Pharmaceuticals reports results from Phase 3 ACTIVATE-Kids studyFebruary 13, 2025 | markets.businessinsider.comEarnings call transcript: Agios Pharm Q4 2024 beats EPS forecast, stock risesFebruary 13, 2025 | msn.comAgios Pharmaceuticals reports Q4 revenue $10.7M, consensus $9.35MFebruary 13, 2025 | markets.businessinsider.comAgios Pharmaceuticals targets multi-billion-dollar growth with Pyrukynd expansion in 2025February 13, 2025 | msn.comAgios Pharmaceuticals, Inc. (AGIO) Q4 2024 Earnings Call TranscriptFebruary 13, 2025 | seekingalpha.comAgios Pharmaceuticals, Inc. 2024 Q4 - Results - Earnings Call PresentationFebruary 13, 2025 | seekingalpha.comAgios Reports Fourth Quarter and Full Year 2024 Financial Results and Recent Business HighlightsFebruary 13, 2025 | globenewswire.comAgios' Phase 3 ACTIVATE-Kids Study of Mitapivat in Children with Pyruvate Kinase (PK) Deficiency Not Regularly Transfused Met Primary EndpointFebruary 13, 2025 | globenewswire.comRep. Gilbert Ray Cisneros, Jr. Buys Agios Pharmaceuticals, Inc. (NASDAQ:AGIO) StockRepresentative Gilbert Ray Cisneros, Jr. (D-California) recently bought shares of Agios Pharmaceuticals, Inc. (NASDAQ:AGIO). In a filing disclosed on February 11th, the Representative disclosed that they had bought between $1,001 and $15,000 in Agios Pharmaceuticals stock on January 29th. The tradeFebruary 13, 2025 | marketbeat.comAgios Pharmaceuticals (AGIO) Expected to Announce Quarterly Earnings on ThursdayAgios Pharmaceuticals (NASDAQ:AGIO) will be releasing earnings before the market opens on Thursday, February 20, Financial Modeling Prep reports. (Register for Conference Call at http://mmm.wallstreethorizon.com/u.asp?u=661768)February 13, 2025 | marketbeat.comAgios Pharmaceuticals, Inc. (AGIO): A Cheap Biotech Stock to Invest In NowFebruary 12, 2025 | uk.finance.yahoo.comC4 Therapeutics stock plunges to 52-week low of $3.24February 11, 2025 | msn.comAgios Pharmaceuticals price target lowered to $54 from $55 at BofAFebruary 11, 2025 | markets.businessinsider.com Remove Ads Get Agios Pharmaceuticals News Delivered to You Automatically Sign up to receive the latest news and ratings for AGIO and its competitors with MarketBeat's FREE daily newsletter. Email Address AGIO Media Mentions By Week AGIO Media Sentiment Learn about the media sentiment score. Each headline receives a score ranging from 2 (good news) to -2 (bad news). Our company news sentiment scores track the average news sentiment of articles about each company over the most recent 7 days in order to identify companies that are receiving positive press. AGIO News Sentiment▼1.040.78▲Average Medical News Sentiment AGIO News Coverage Learn about the media coverage comparison. We track news headlines from hundreds of news outlets and tag them by company. This chart compares the number of articles about this company in the last seven days compared with the average number of articles about this company on a typical week. AGIO Articles This Week▼95▲AGIO Articles Average Week Remove Ads Get Agios Pharmaceuticals News Delivered to You Automatically Sign up to receive the latest news and ratings for AGIO and its competitors with MarketBeat's FREE daily newsletter. Email Address Related Companies and Tools Related Companies Revolution Medicines News BridgeBio Pharma News Lantheus News TG Therapeutics News Legend Biotech News Axsome Therapeutics News Telix Pharmaceuticals Limited American Depositary Shares News Blueprint Medicines News Krystal Biotech News Nuvalent News Headlines Tools Trending Media MentionsHigh Media Sentiment StocksLive News FeedMarketBeat OriginalsStock Ideas This page (NASDAQ:AGIO) was last updated on 3/28/2025 by MarketBeat.com Staff From Our PartnersElon Warns: Exec Order 14024 Targets DollarExecutive Order 14024 is paving the way for irreversible damage to the dollar's value—threatening your wealth,...Priority Gold | SponsoredWarning: “DOGE Collapse” imminentElon Strikes Back You may already sense that the tide is turning against Elon Musk and DOGE. Just this week...Altimetry | SponsoredYour Wealth is Under AttackPlease don't wait—this is your moment to take action. Download your Wealth Protection Guide now, claim your fr...American Alternative | SponsoredTrump Treasure April 19Thanks to President Trump… A $900 investment across5 specific cryptos… Could gain 12,000% so quickly tha...Paradigm Press | SponsoredDo this Before Elon's Reveal on April 23rdElon’s newest tech could pay you an extra $30,000 a year — while you sleep. It’s smaller than a quarter but...Brownstone Research | SponsoredA market crash is coming—here’s whenThe stock market cycle I've used to identify the most likely day of the next market crash is the exact same in...Chaikin Analytics | SponsoredA $6.9 Trillion Cash Tsunami Is Coming – Move Your Money NOWExpert: "Prepare For the Mother of All Melt-Ups" In the wake of Wall Street volatility, stock-picking legen...Stansberry Research | SponsoredTwo Unmistakable Patterns Return…The signs suggest we're entering one of those rare periods now. That's why Central Banks are buying gold at...Golden Portfolio | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Agios Pharmaceuticals, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Agios Pharmaceuticals With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Buy AGIO Stock Free AGIO Stock Alerts